Literature DB >> 12061890

Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.

Soon Hyung Woo1, Sylvie Frechette, Elie Abou Khalil, Giliane Bouchain, Arkadii Vaisburg, Naomy Bernstein, Oscar Moradei, Silvana Leit, Martin Allan, Marielle Fournel, Marie-Claude Trachy-Bourget, Zuomei Li, Jeffrey M Besterman, Daniel Delorme.   

Abstract

A series of new, structurally simple trichostatin A (TSA)-like straight chain hydroxamates were prepared and evaluated for their ability to inhibit partially purified human histone deacetylase 1 (HDAC-1). Some of these compounds such as 8m, 8n, 12, and 15b exhibited potent HDAC inhibitory activity with low nanomolar IC(50) values, comparable to natural TSA. These compounds induce hyperacetylation of histones in T24 human cancer cells and significantly inhibit proliferation in various human cancer cells. They also induce expression of p21 and cause cell cycle blocks in human cancer cells. In this paper, we describe the synthesis of these new compounds as well as structure-activity relationship results from enzyme inhibition and alterations in cellular function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12061890     DOI: 10.1021/jm020154k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.

Authors:  Melinda C Myzak; Karin Hardin; Rong Wang; Roderick H Dashwood; Emily Ho
Journal:  Carcinogenesis       Date:  2005-11-09       Impact factor: 4.944

Review 2.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

3.  Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.

Authors:  Anton V Bieliauskas; Sujith V W Weerasinghe; Mary Kay H Pflum
Journal:  Bioorg Med Chem Lett       Date:  2007-02-08       Impact factor: 2.823

4.  Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain.

Authors:  Young Jun Seo; Lisa Muench; Alicia Reid; Jinzhu Chen; Yeona Kang; Jacob M Hooker; Nora D Volkow; Joanna S Fowler; Sung Won Kim
Journal:  Bioorg Med Chem Lett       Date:  2013-10-30       Impact factor: 2.823

5.  Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228).

Authors:  Thomas J Greshock; Deidre M Johns; Yasuo Noguchi; Robert M Williams
Journal:  Org Lett       Date:  2008-01-19       Impact factor: 6.005

6.  Molecular dynamics-guided receptor-dependent 4D-QSAR studies of HDACs inhibitors.

Authors:  Zhihao Hu; Qianxia Lin; Haiyun Liu; Tiansheng Zhao; Bowen Yang; Guogang Tu
Journal:  Mol Divers       Date:  2021-02-24       Impact factor: 2.943

Review 7.  Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.

Authors:  Jun Yang; Chaoju Gong; Qinjian Ke; Zejun Fang; Xiaowen Chen; Ming Ye; Xi Xu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

8.  Virtual screening and experimental validation of novel histone deacetylase inhibitors.

Authors:  Yan-Xin Huang; Jian Zhao; Qiu-Hang Song; Li-Hua Zheng; Cong Fan; Ting-Ting Liu; Yong-Li Bao; Lu-Guo Sun; Li-Biao Zhang; Yu-Xin Li
Journal:  BMC Pharmacol Toxicol       Date:  2016-07-21       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.